Core Viewpoint - The company emphasizes its commitment to "technology-led, innovation-driven" strategies, focusing on accelerating technological innovation and advancing the development of improved new drugs and high-end complex formulations [1] Group 1: Technological Innovation - The company is actively promoting the construction of innovative technology platforms, including sustained-release and membrane dosage forms [1] - Collaboration with East China University of Science and Technology and other higher education institutions is ongoing in the field of synthetic biology [1] Group 2: Research and Development - Specific details regarding the company's R&D efforts will be disclosed in the relevant sections of the annual report [1]

Core Viewpoint - The establishment of the Hainan Free Trade Port is expected to provide a broader platform for companies, particularly benefiting the development of high-end complex formulations, biopharmaceuticals, and specialty traditional Chinese medicine products [1] Group 1: Policy Benefits - The new policies significantly lower operational costs for companies by exempting certain goods from import tariffs, value-added tax, and consumption tax [1] - The Hainan Free Trade Port is creating a complete industrial innovation ecosystem, supporting the entire chain from research and development to clinical trials and manufacturing [1] - The company has already benefited from these policies, with its new drug, Fluorofenone capsules, being included in the list of breakthrough treatment varieties by the National Medical Products Administration [1] Group 2: Talent and Market Strategy - The talent policies in Hainan are attractive, with personal income tax for high-end and scarce talents capped at 15%, directly reducing labor costs for companies [2] - The company is actively leveraging the advantages of the Boao Lecheng pilot zone to introduce more high-quality foreign innovative products, aiming to capture market share early [2] Group 3: Innovation and Market Expansion - The company has restructured its R&D system, forming a 92-member team and developing advanced technology platforms for biobased synthesis and cyclic peptide drug development [2] - The company is focusing on market expansion strategies, with products like Amikacin showing growth despite procurement pressures, and has successfully participated in national procurement [2] - The company is also seeing significant growth in exports of raw materials and formulations [2] Group 4: Reform and Future Outlook - The company is undergoing reforms to dispose of non-core assets and improve operational efficiency, which is expected to enhance corporate vitality and support innovation [3] - Looking ahead, the company plans to utilize the benefits of the free trade port to drive high-quality development, focusing on a collaborative growth model across various sectors [3] - The company aims to enhance the efficiency of the entire industry chain and expand its global market presence by building a cross-border e-commerce platform [4]